Bridgewater Associates LP Sells 20,472 Shares of DaVita Inc. (NYSE:DVA)

Bridgewater Associates LP trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 25.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,226 shares of the company's stock after selling 20,472 shares during the quarter. Bridgewater Associates LP owned about 0.07% of DaVita worth $9,873,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its position in DaVita by 29.6% in the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock worth $6,942,000 after purchasing an additional 11,454 shares during the period. Comerica Bank lifted its holdings in DaVita by 41.4% in the 1st quarter. Comerica Bank now owns 34,431 shares of the company's stock valued at $4,753,000 after acquiring an additional 10,074 shares during the last quarter. Quest Partners LLC acquired a new position in shares of DaVita in the 3rd quarter worth approximately $669,000. MBB Public Markets I LLC bought a new stake in shares of DaVita in the 2nd quarter worth approximately $582,000. Finally, Chase Investment Counsel Corp lifted its stake in DaVita by 56.3% during the third quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company's stock valued at $5,423,000 after purchasing an additional 11,912 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DVA has been the topic of several recent research reports. UBS Group lifted their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. Finally, Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $161.80.

DaVita Stock Up 0.6 %

Shares of NYSE DVA traded up $0.94 during mid-day trading on Friday, reaching $166.57. The company had a trading volume of 314,276 shares, compared to its average volume of 821,067. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. DaVita Inc. has a twelve month low of $99.18 and a twelve month high of $169.51. The stock's 50 day moving average is $158.52 and its 200-day moving average is $149.10. The stock has a market capitalization of $13.66 billion, a PE ratio of 18.03, a price-to-earnings-growth ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the business earned $2.85 earnings per share. As a group, equities analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.00% of the company's stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.